Health Care Blog June 29, 2021
Jessica DaMassa, WTF Health

For those keeping score at home, Glen Tullman is scaling up Transcarent faster than he did Livongo. The startup just closed a $58M Series B, bringing its total funding just shy of $100M. In less than 8 months. What’s the hurry? Have we ordered the balloons for the IPO yet? Glen says he’s out to fix the core problem first, and, in this interview, we get into the details about what that problem statement is all about and you might be surprised.

This is more of a payment model story than anyone may have all initially realized. And, while we may keep trying to put Transcarent into the “healthcare navigator” box or call it a “second opinion service” or a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Employer, Insurance, Interview / Q&A, Payment Models, Self-insured, Trends
Accolade Gets a Do-Over With Transcarent’s $621M Acquisition
Transcarent to buy Accolade for $621M
Transcarent to acquire fellow health benefits navigator Accolade for $621M
Transcarent To Acquire Accolade
Transcarent to acquire Accolade for $621 million

Share This Article